Given that NANOG and pEGFR have been defined as poor prognostic factors in patients with cervical cancer, we further assessed the potential association between NANOG-TRPV1-pEGFR expression and chemoradiation resistance in human cervical cancer by immunohistochemistry (Fig. 6a). Here, TRPV1 is linked to cervical cancer.